Verona Pharma — Patent Portfolio
1 drug with active patents · 5 active patents · 0 expired · 0 biologics with BPCIA exclusivity
Verdict Verona Pharma's patent portfolio is moderately vulnerable, with a significant cliff year in 2031 and no revenue at risk in the next 5 years.
Portfolio overview Verona Pharma has a total of 1 drug with patents, out of 1 total drugs in their portfolio. Their patent estate consists of 5 active US patents with an average vulnerability score of 64, indicating a moderate level of vulnerability. Notably, none of their patents are considered ironclad, while 2 are considered vulnerable.
Cliff calendar In 2031, 1 drug will lose exclusivity, including Ohtuvayre. This marks a significant cliff year for the company, with a notable loss of exclusivity for one of their key products.
Most exposed drugs The top drug facing near-term loss of exclusivity is Ohtuvayre, with an earliest active patent expiry date of 2031-08-21 and an average vulnerability score of 64. Unfortunately, we do not have information on the annual revenue for this product.
Biologic exclusivity Verona Pharma does not have any biologics in their portfolio, and therefore does not have any biologic exclusivity to consider.
Strategic implications With no revenue at risk in the next 5 years, Verona Pharma has a relatively stable patent estate. However, the company should consider lifecycle moves to maintain their competitive position, such as subQ switches, label extensions, or combination filings, to maximize the value of their remaining patents.
Loss of exclusivity calendar · next 12 years
Drugs facing US patent or BPCIA biologic exclusivity loss per year. Click any year to see the broader cliff calendar for the industry.
Patent estate by drug
Ohtuvayre (ENSIFENTRINE)
Cliff 2031 · 5y-
US9062047
Vuln 81
2031-08-21
This patent protects a specific crystalline form of a pyrimido[6,1-A] isoquinolin-4-one compound, also known as a polymorph of N-{2-[(2E)-2-(mesitylimino)-9,10-dimethoxy-4-oxo-6,7-…
-
US9956171
Vuln 75
2035-09-15
This patent protects a liquid inhalation formulation containing RPL554, a pharmaceutical composition suitable for administration by inhalation.
-
US10945950
Vuln 55
2035-09-15
This patent protects a liquid inhalation formulation containing RPL554 or a pharmaceutically acceptable salt thereof.
Patent classification breakdown · active patents
By US patent type. Method-of-use patents are most vulnerable to design-around; composition-of-matter patents are the strongest protection.
- Formulation 3 patents
- Method of Use 2 patents
Sources
- FDA Orange Book — small-molecule patents listed against approved NDAs.
- FDA Purple Book — biologic BPCIA 12-year reference product exclusivity.
- USPTO Patent Public Search — title, abstract, claim text grounding.
- AI summaries generated by Drug Landscape, grounded in source claim text.
Patent term extensions (PTR, SPC, pediatric exclusivity) may shift effective expiry. Not legal advice.
Track Verona Pharma's patent estate
Daily alerts when vulnerability scores shift, patents expire, or IPRs are filed. Free tier: 3 watches. Pro tier (£199/mo): 50 watches + daily AI Pharma IP Brief.
↓ CSV export